Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TWST
stocks logo

TWST

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2026Q2
FY2026Q3
100.38M
+13.15%
-0.436
-17.74%
105.38M
+13.57%
-0.432
-34.57%
109.63M
+14.13%
-0.345
-204.45%
Estimates Revision
The market is revising Downward the revenue expectations for Twist Bioscience Corporation (TWST) for FY2026, with the revenue forecasts being adjusted by -2.33% over the past three months. During the same period, the stock price has changed by 27.37%.
Revenue Estimates for FY2026
Revise Downward
down Image
-2.33%
In Past 3 Month
EPS Estimates for FY2026
Revise Upward
up Image
+15.88%
In Past 3 Month
Stock Price
Go Up
up Image
+27.37%
In Past 3 Month
Wall Street analysts forecast TWST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TWST is 38.00 USD with a low forecast of 32.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast TWST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TWST is 38.00 USD with a low forecast of 32.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 32.810
sliders
Low
32.00
Averages
38.00
High
42.00
Current: 32.810
sliders
Low
32.00
Averages
38.00
High
42.00
Barclays
Overweight
downgrade
$40 -> $37
2025-11-17
Reason
Barclays
Price Target
$40 -> $37
2025-11-17
downgrade
Overweight
Reason
Barclays lowered the firm's price target on Twist Bioscience to $37 from $40 and keeps an Overweight rating on the shares. The firm says management's description of being "commercially violent" continues to win market share. However, questions on Twist's market opportunities remain, particularly in synthetic biology, the analyst tells investors in a research note.
Stephens
Steven Etoch
Overweight
initiated
$41
2025-11-03
Reason
Stephens
Steven Etoch
Price Target
$41
2025-11-03
initiated
Overweight
Reason
Stephens analyst Steven Etoch initiated coverage of Twist Bioscience with an Overweight rating and $41 price target. Twist operates a differentiated, technology-driven DNA synthesis platform with proprietary silicon chip technology, inspired by semiconductor manufacturing, that provides advantages in cost, speed, and scale. While competition remains intense, Twist's cost leadership and prior investments are driving share gains and although the path to profitability is "not fully de-risked," the firm sees a growing line of sight driven by strategic execution and commercial momentum, the analyst tells investors.
Evercore ISI
Outperform
downgrade
$50 -> $46
2025-08-04
Reason
Evercore ISI
Price Target
$50 -> $46
2025-08-04
downgrade
Outperform
Reason
Evercore ISI lowered the firm's price target on Twist Bioscience to $46 from $50 and keeps an Outperform rating on the shares. The firm updated the company's model post the fiscal Q3 report. It views the quarter as "decent" with solid gross margins. Twist has solid momentum entering fiscal 2026, the analyst tells investors in a research note.
TD Cowen
Brendan Smith
Buy
downgrade
$58 -> $36
2025-08-04
Reason
TD Cowen
Brendan Smith
Price Target
$58 -> $36
2025-08-04
downgrade
Buy
Reason
TD Cowen analyst Brendan Smith lowered the firm's price target on Twist Bioscience to $36 from $58 and keeps a Buy rating on the shares. The stock has been under pressure following Q3 revenue that was in line with guidance and the narrowing of FY25 guidance as investor hoped for "a clean beat/raise." The firm, which is trimming near-term estimstes for SynBio, largely offset by consistent NGS growth into next year, now assigns a multiple closer to peer trading multiples to reflect updated growth assumptions.
Barclays
Luke Sergott
Buy
Maintains
$58 → $45
2025-04-10
Reason
Barclays
Luke Sergott
Price Target
$58 → $45
2025-04-10
Maintains
Buy
Reason
JP Morgan
Rachel Vatnsdal
Sell
Maintains
$35 → $40
2025-02-04
Reason
JP Morgan
Rachel Vatnsdal
Price Target
$35 → $40
2025-02-04
Maintains
Sell
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Twist Bioscience Corp (TWST.O) is -22.06, compared to its 5-year average forward P/E of -17.72. For a more detailed relative valuation and DCF analysis to assess Twist Bioscience Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-17.72
Current PE
-22.06
Overvalued PE
-5.34
Undervalued PE
-30.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-18.39
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-4.78
Undervalued EV/EBITDA
-32.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
13.91
Current PS
0.00
Overvalued PS
29.29
Undervalued PS
-1.48
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 634.68% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

TWST News & Events

Events Timeline

(ET)
2025-11-14
07:39:59
Twist Bioscience projects FY26 revenue between $425M and $435M, aligning with consensus of $434.81M.
select
2025-11-14
07:37:57
Twist Bioscience Reports Q1 Revenue Between $100M and $101M, Matching Consensus of $100.75M
select
2025-11-14
07:36:17
Twist Bioscience Announces Q4 Earnings Per Share of 45 Cents, Below Consensus Estimate of 50 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-04Newsfilter
Twist Bioscience Launches Research-Grade Plasmid DNA Preps with 4-Day Turnaround
  • Product Innovation: Twist Bioscience has launched animal origin-free and transfection-grade plasmid DNA preps, with target yield options ranging from 4ug to 10ug, aimed at supporting pharmaceutical and biotech customers in their preclinical studies by enhancing product quality and consistency.
  • Delivery Efficiency Improvement: The new product offers a turnaround time of just four business days, which not only meets customer demands for rapid delivery but also reduces operational risks by streamlining supply chains.
  • Market Adaptability: Twist's plasmid preps meet stringent customer quality requirements for low endotoxin and animal origin-free standards, ensuring reduced variability and risk during cell transfection, thereby enhancing customer trust.
  • Strategic Positioning: By providing high-quality DNA synthesis tools, Twist Bioscience not only accelerates its customers' R&D processes but also solidifies its market leadership in synthetic biology, driving sustainable development.
[object Object]
Preview
7.0
12-03Globenewswire
Twist Bioscience Faces Allegations of Financial Fraud and Misleading Statements
  • Shareholder Litigation Investigation: Kuehn Law, PLLC is investigating whether officers of Twist Bioscience breached their fiduciary duties to shareholders, involving significant false statements that could harm shareholder interests.
  • False Statement Allegations: A federal securities lawsuit claims insiders at Twist Bioscience overstated the commercial viability of its synthetic DNA technology while failing to disclose adverse facts about the company's operations, potentially misleading investors.
  • Accounting Fraud Claims: Allegations of accounting fraud and unsustainable pricing strategies may have led to a severe overestimation of the company's financial condition, misleading investors regarding its future prospects.
  • Shareholder Rights Protection: Kuehn Law urges shareholders to contact their attorney promptly to protect their rights, highlighting the importance of shareholder involvement in maintaining the integrity of financial markets and the necessity of participation.
[object Object]
Preview
6.0
11-17Benzinga
Barclays Keeps Overweight Rating on Twist Bioscience, Reduces Price Target to $37

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, fostering a collaborative environment for sharing market intelligence.

  • Market Success: Traders utilize Benzinga Pro's resources to gain a competitive edge and improve their chances of winning in the markets daily.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Twist Bioscience Corp (TWST) stock price today?

The current price of TWST is 32.81 USD — it has increased 5.26 % in the last trading day.

arrow icon

What is Twist Bioscience Corp (TWST)'s business?

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.

arrow icon

What is the price predicton of TWST Stock?

Wall Street analysts forecast TWST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TWST is 38.00 USD with a low forecast of 32.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Twist Bioscience Corp (TWST)'s revenue for the last quarter?

Twist Bioscience Corp revenue for the last quarter amounts to 99.01M USD, increased 16.88 % YoY.

arrow icon

What is Twist Bioscience Corp (TWST)'s earnings per share (EPS) for the last quarter?

Twist Bioscience Corp. EPS for the last quarter amounts to -0.45 USD, decreased -23.73 % YoY.

arrow icon

What changes have occurred in the market's expectations for Twist Bioscience Corp (TWST)'s fundamentals?

The market is revising Downward the revenue expectations for Twist Bioscience Corporation (TWST) for FY2026, with the revenue forecasts being adjusted by -2.33% over the past three months. During the same period, the stock price has changed by 27.37%.
arrow icon

How many employees does Twist Bioscience Corp (TWST). have?

Twist Bioscience Corp (TWST) has 979 emplpoyees as of December 05 2025.

arrow icon

What is Twist Bioscience Corp (TWST) market cap?

Today TWST has the market capitalization of 2.01B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free